Skip to main content
    K

    Krystal Biotech Inc (KRYS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $297.90
    -7.33 (-2.40%)

    Market Cap: $9.05B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Krystal Biotech Inc (KRYS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Krystal Biotech (KRYS) has a market cap of $9.05B and an enterprise value of $8.58B. It kept 47.91% of revenue as net income over the last 12 months. Revenue grew 25.96% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 5.12% below the market cap, as cash exceeds debt.

    Market Cap$9.05B
    Enterprise Value$8.58B
    Latest price (Nov 17, 2026)$297.90

    Key Dates

    The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 15, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.27% in the quarter ended Sep 30, 2026 and grew 1.54% a year over 2 years.

    Shares Outstanding29.61M
    Shares Change (YoY)+2.27%
    Shares Change (QoQ)+0.27%
    Share Count Growth (2Y CAGR)+1.54%

    Valuation Ratios

    Sales and book value multiples are 18.8x and 6.1x.

    P/E Ratio40.4x
    Forward P/E38.0x
    P/S Ratio18.8x
    Forward P/S18.2x
    P/B Ratio6.1x
    P/FCF Ratio28.4x
    P/OCF Ratio27.9x
    PEG Ratio0.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 35.7x EBITDA and 27.0x free cash flow.

    EV / Earnings38.1x
    EV / Sales18.3x
    EV / EBITDA35.7x
    EV / FCF27.0x

    Price Statistics

    The stock is up 48.05% over 52 weeks and trades 8.50% below its 50-day average.

    Beta (1Y)0.76
    52-Week Change+48.05%
    1-Month Change-5.90%
    3-Month Change-10.49%
    6-Month Change+2.11%
    5-Year Change+563.39%
    Total Return (1Y)+48.05%
    Total Return (3Y CAGR)+41.98%
    Total Return (5Y CAGR)+42.90%
    Return vs SPY (1Y)+33.94%
    Max Drawdown (1Y)-21.75%
    Max Drawdown (3Y)-42.26%
    Sharpe Ratio (1Y)0.96
    Correlation with SPY (1Y)0.26
    50-Day Average$325.56
    200-Day Average$309.80
    52-Week Range$203.18 to $382.54
    RSI (14 Days)39.1
    Average Volume (20 Days)315.85K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.89x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.89x
    Quick Ratio7.53x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 15.68% over the last 12 months, against a 5-year average of -2.18%.

    Return on Equity (ROE)15.68%
    Return on Assets (ROA)14.20%
    ROE (5Y Average)-2.18%
    ROA (5Y Average)-2.21%
    ROIC (5Y Average)13.23%
    Asset Turnover0.33x
    Inventory Turnover0.56x
    Receivables Turnover3.46x
    Cash Conversion Cycle160 days

    Taxes

    Income tax took 12.99% of pretax income over the last 12 months.

    Income Tax (TTM)$33.63M
    Effective Tax Rate12.99%

    Scores

    KRYS has an Altman Z-Score of 36.86, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score36.86
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $470.02M over the last 12 months.

    Revenue$470.02M
    Revenue Growth (YoY)+25.96%
    Gross Profit$443.12M
    Operating Income$227.69M
    Pretax Income$258.80M
    Net Income$225.17M
    Reported EPS (TTM)$7.37

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.57% of the $1.59B in total assets.

    Cash and Equivalents$462.84M
    Total Debt$0
    Net Cash$462.84M
    Net Cash Per Share$15.63
    Working Capital$979.62M
    Shareholder Equity$1.44B
    Book Value Per Share$48.48
    Total Assets$1.59B
    Total Liabilities$150.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $13.85M of capital spending, operating cash flow left $310.08M of free cash flow.

    Operating Cash Flow$323.93M
    Capital Expenditures$13.85M
    Free Cash Flow$310.08M
    FCF Per Share$10.48
    Depreciation and Amortization$6.60M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 48.44%.

    Gross Margin94.27%
    Operating Margin48.44%
    Pretax Margin55.06%
    Net Margin47.91%
    FCF Margin65.97%

    Growth

    Book Value Per Share Growth (2Y CAGR)+22.76%
    Tangible Book Per Share Growth (2Y CAGR)+22.76%

    Revenue and profit by year

    Dividends and Yields

    KRYS does not pay a dividend. Its free cash flow yield is 3.52%.

    Earnings Yield2.48%
    FCF Yield3.52%
    Shareholder Yield0.00%

    Peer Position

    Against 3 similar companies, KRYS has the 2nd highest P/E.

    P/E Ratio40.4x vs 39.5x median
    P/S Ratio18.8x vs 15.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+25.96% vs +61.04% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 27.73% and EPS growth at 16.07% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+27.73%
    EPS Growth Forecast (2Y CAGR)+16.07%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KRYS

    What is KRYS's market cap?

    Krystal Biotech has a market cap of $9.05B. Its enterprise value, which adds debt and subtracts cash, is $8.58B.

    What is KRYS's P/E ratio?

    Krystal Biotech has a trailing P/E ratio of 40.4x and a forward P/E of 38.0x.

    How many shares of KRYS are outstanding?

    Krystal Biotech has 29.61M shares outstanding. The count is up 2.27% from a year earlier.

    Does KRYS pay a dividend?

    No. Krystal Biotech does not pay a dividend.

    How much debt does KRYS have?

    Krystal Biotech has $0 of total debt and $462.84M of cash and equivalents, a net cash position of $462.84M.